

Atopic Dermatitis Toolkit

Clinical Overview

Resource	Address
Drucker AM, Wang AR, Li WQ, Sevetson E, Block JK, Qureshi AA. The burden of atopic dermatitis: Summary of a report for the National Eczema Association. <i>J Invest Dermatol.</i> 2017;137(1):26-30. doi:10.1016/j.jid.2016.07.012	https://pubmed.ncbi.nlm.nih.gov/27616422/
Frazier W, Bhardwaj N. Atopic dermatitis: Diagnosis and treatment. <i>Am Fam Physician.</i> 2020;101(10):590-598. PMID:32412211	https://pubmed.ncbi.nlm.nih.gov/32412211/
Frischmeyer-Guerrerio PA, Rasooly M, Gu W, et al. IgE testing can predict food allergy status in patients with moderate to severe atopic dermatitis. <i>Ann Allergy Asthma Immunol.</i> 2019;122(4):393-400.e2. doi:10.1016/j.anai.2019.01.001	https://pubmed.ncbi.nlm.nih.gov/30639434/
Gaudinski MR, Milner JD. Atopic dermatitis and allergic urticaria: Cutaneous manifestations of immunodeficiency. <i>Immunol Allergy Clin North Am.</i> 2017;37(1):1-10. doi:10.1016/j.iac.2016.08.016	https://pubmed.ncbi.nlm.nih.gov/27886899/
Guttman-Yassky E, Krueger JG, Lebwohl MG. Systemic immune mechanisms in atopic dermatitis and psoriasis with implications for treatment. <i>Exp Dermatol.</i> 2018;27(4):409-417. doi:10.1111/exd.13336	https://pubmed.ncbi.nlm.nih.gov/28266782/
Hulpusch C, Weins AB, Traidl-Hoffmann C, Reiger M. A new era of atopic eczema research: Advances and highlights. <i>Allergy.</i> 2021;76(11):3408-3421. doi:10.1111/all.15058	https://pubmed.ncbi.nlm.nih.gov/34407212/
Kantor R, Silverberg JI. Environmental risk factors and their role in the management of atopic dermatitis. <i>Expert Rev Clin Immunol.</i> 2017;13(1):15-26. doi:10.1080/1744666X.2016.1212660	https://pubmed.ncbi.nlm.nih.gov/27417220/
Li H, Zhang Z, Zhang H, Guo Y, Yao Z. Update on the pathogenesis and therapy of atopic dermatitis. <i>Clin Rev Allergy Immunol.</i> 2021;61(3):324-338. doi:10.1007/s12016-021-08880-3	https://pubmed.ncbi.nlm.nih.gov/34338977/
McLean WHI. Filaggrin failure - from ichthyosis vulgaris to atopic eczema and beyond. <i>Br J Dermatol.</i> 2016;175(suppl S2):4-7. doi:10.1111/bjd.14997	https://pubmed.ncbi.nlm.nih.gov/27667308/

Napolitano M, Megna M, Patruno C, Gisondi P, Ayala F, Balato N. Adult atopic dermatitis: A review. <i>G Ital Dermatol Venereol</i> . 2016;151(4):403-411. PMID:25658440	https://pubmed.ncbi.nlm.nih.gov/25658440/
Paller AS, Kong HH, Seed P, et al. The microbiome in patients with atopic dermatitis. <i>J Allergy Clin Immunol</i> . 2019;143(1):26-35. doi:10.1016/j.jaci.2018.11.015	https://pubmed.ncbi.nlm.nih.gov/30476499/
Paul D, Papier A. Scabies: Refine your exam, avoid these diagnostic pitfalls. <i>J Fam Pract</i> . 2020;69(1):10-17. PMID:32017829	https://pubmed.ncbi.nlm.nih.gov/32017829/
Sahni V, Balogh EA, Strowd LC, Feldman SR. The evolving atopic dermatitis management landscape. <i>Expert Opin Pharmacother</i> . 2022;23(4):517-526. doi:10.1080/14656566.2021.1999412	https://pubmed.ncbi.nlm.nih.gov/34758685/
Salimian J, Salehi Z, Ahmadi A, et al. Atopic dermatitis: Molecular, cellular, and clinical aspects. <i>Mol Biol Rep</i> . 2022;49(4):3333-3348. doi:10.1007/s11033-021-07081-7	https://pubmed.ncbi.nlm.nih.gov/34989960/
Schmitt J, Buske-Kirschbaum A, Tesch F, et al. Increased attention-deficit/hyperactivity symptoms in atopic dermatitis are associated with history of antihistamine use. <i>Allergy</i> . 2018;73(3):615-626. doi:10.1111/all.13326	https://pubmed.ncbi.nlm.nih.gov/28975640/
Silverberg JI, Gelfand JM, Margolis DJ, et al. Association of atopic dermatitis with allergic, autoimmune, and cardiovascular comorbidities in US adults. <i>Ann Allergy Asthma Immunol</i> . 2018;121(5):604-612.e3. doi:10.1016/j.anai.2018.07.042	https://pubmed.ncbi.nlm.nih.gov/30092266/
Silverberg JI. Comorbidities and the impact of atopic dermatitis. <i>Ann Allergy Asthma Immunol</i> . 2019;123(2):144-151. doi:10.1016/j.anai.2019.04.020	https://pubmed.ncbi.nlm.nih.gov/31034875/
Silverberg JI. Revolutionizing atopic dermatitis. <i>Cutis</i> . 2019;104(3):142-143. PMID:31675396	https://pubmed.ncbi.nlm.nih.gov/31675396/
Thijs JL, de Bruin-Weller MS, Hijnen D. Current and future biomarkers in atopic dermatitis. <i>Immunol Allergy Clin North Am</i> . 2017;37:51-61. doi:10.1016/j.iac.2016.08.008	https://pubmed.ncbi.nlm.nih.gov/27886910/

Treatment of Atopic Dermatitis

Resource	Address
Ahn J, Grinich EE, Choi Y, Guttman-Yassky E, Simpson EL. Emerging systemic therapeutic biologics and small molecules for atopic dermatitis: How to decide which treatment is right for your patients. <i>J Allergy Clin Immunol Pract.</i> 2021;9(4):1449-1460. doi:10.1016/j.jaip.2021.02.003	https://pubmed.ncbi.nlm.nih.gov/33838838/
Bissonnette R, Papp KA, Poulin Y, et al. Topical tofacitinib for atopic dermatitis: A phase IIa randomized trial. <i>Br J Dermatol.</i> 2016;175(5):902-911. doi:10.1111/bjd.14871	https://pubmed.ncbi.nlm.nih.gov/27423107/
Brar KK, Nicol NH, Boguniewicz M. Strategies for successful management of severe atopic dermatitis. <i>J Allergy Clin Immunol Pract.</i> 2019;7(1):1-16. doi:10.1016/j.jaip.2018.10.021	https://pubmed.ncbi.nlm.nih.gov/30598172/
Chovatiya R, Paller AS. JAK inhibitors in the treatment of atopic dermatitis. <i>J Allergy Clin Immunol.</i> 2021;148(4):927-940. doi:10.1016/j.jaci.2021.08.009	https://pubmed.ncbi.nlm.nih.gov/34437922/
Cotter DG, Schairer D, Eichenfield L. Emerging therapies for atopic dermatitis: JAK inhibitors. <i>J Am Acad Dermatol.</i> 2018;78(3 suppl 1):S53-S62. doi:10.1016/j.jaad.2017.12.019	https://pubmed.ncbi.nlm.nih.gov/29248518/
Czarnowicki T, He H, Krueger JG, Guttman-Yassky E. Atopic dermatitis endotypes and implications for targeted therapeutics. <i>J Allergy Clin Immunol.</i> 2019;143(1):1-11. doi:10.1016/j.jaci.2018.10.032	https://pubmed.ncbi.nlm.nih.gov/30612663/
Guraya A, Pandher K, Porter CL, et al. Review of the holistic management of pediatric atopic dermatitis. <i>Eur J Pediatr.</i> 2022;181(4):1363-1370. doi:10.1007/s00431-021-04341-3	https://pubmed.ncbi.nlm.nih.gov/35064309/
Guttman-Yassky E, Silverberg JJ, Nemoto O, et al. Baricitinib in adult patients with moderate-to-severe atopic dermatitis: A phase 2 parallel, double-blinded, randomized placebo-controlled multiple-dose study. <i>J Am Acad Dermatol.</i> 2019;80(4):913-921.e9. doi:10.1016/j.jaad.2018.01.018	https://pubmed.ncbi.nlm.nih.gov/29410014/
Jarnagin K, Chanda S, Coronado D, et al. Crisaborole topical ointment, 2%: A nonsteroidal, topical, anti-inflammatory phosphodiesterase 4 inhibitor in clinical development for the treatment of atopic dermatitis. <i>J Drugs Dermatol.</i> 2016;15(4):390-396. PMID:27050693	https://pubmed.ncbi.nlm.nih.gov/27050693/

Li AW, Yin ES, Antaya RJ. Topical corticosteroid phobia in atopic dermatitis: A systematic review. <i>JAMA Dermatol.</i> 2017;153(10):1036-1042. doi:10.1001/jamadermatol.2017.2437	https://pubmed.ncbi.nlm.nih.gov/28724128/
Mobasher P, Heydari Seradj M, Raffi J, Juhasz M, Atanaskova Mesinkovska N. Oral small molecules for the treatment of atopic dermatitis: A systematic review. <i>J Dermatolog Treat.</i> 2019;30(6):550-557. doi:10.1080/09546634.2018.1544412	https://pubmed.ncbi.nlm.nih.gov/30501539/
Pan Y, Xu L, Qiao J, Fang H. A systematic review of ustekinumab in the treatment of atopic dermatitis. <i>J Dermatolog Treat.</i> 2018;29(6):539-541. doi:10.1080/09546634.2017.1406894	https://pubmed.ncbi.nlm.nih.gov/29164954/
Ruzicka T, Hanifin JM, Furue M, et al. Anti-interleukin-31 receptor A antibody for atopic dermatitis. <i>N Engl J Med.</i> 2017;376(9):826-835. doi:10.1056/NEJMoa1606490	https://pubmed.ncbi.nlm.nih.gov/28249150/
Schlessinger J, Shepard JS, Gower R, et al. Safety, effectiveness, and pharmacokinetics of crisaborole in infants aged 3 to < 24 months with mild-to-moderate atopic dermatitis: A phase IV open-label study (CrisADe CARE 1). <i>Am J Clin Dermatol.</i> 2020;21(2):275-284. doi:10.1007/s40257-020-00510-6	https://pubmed.ncbi.nlm.nih.gov/32212104/
Siegfried EC, Jaworski JC, Eichenfield LF, et al. Developing drugs for treatment of atopic dermatitis in children (≥3 months to <18 years of age): Draft guidance for industry. <i>Pediatr Dermatol.</i> 2018;35(3):303-322. doi:10.1111/pde.13452	https://pubmed.ncbi.nlm.nih.gov/29600515/
Simpson EL, Imafuku S, Poulin Y, et al. A phase 2 randomized trial of apremilast in patients with atopic dermatitis. <i>J Invest Dermatol.</i> 2019;139(5):1063-1072. doi:10.1016/j.jid.2018.10.043	https://pubmed.ncbi.nlm.nih.gov/30528828/
Simpson EL, Papp KA, Blauvelt A, et al. Efficacy and safety of upadacitinib in patients with moderate to severe atopic dermatitis: Analysis of follow-up data from the Measure Up 1 and Measure Up 2 randomized clinical trials. <i>JAMA Dermatol.</i> 2022;158(4):404-413. doi:10.1001/jamadermatol.2022.0029	https://pubmed.ncbi.nlm.nih.gov/35262646/

Simpson EL, Parnes JR, She D, et al. Tezepelumab, an anti-thymic stromal lymphopoietin monoclonal antibody, in the treatment of moderate to severe atopic dermatitis: A randomized phase 2a clinical trial. <i>J Am Acad Dermatol</i> . 2019;80(4):1013-1021. doi:10.1016/j.jaad.2018.11.059	https://pubmed.ncbi.nlm.nih.gov/30550828/
Thyssen JP, de Bruin-Weller MS, Paller AS, et al. Conjunctivitis in atopic dermatitis patients with and without dupilumab therapy - international eczema council survey and opinion. <i>J Eur Acad Dermatol Venereol</i> . 2019;33(7):1224-1231. doi:10.1111/jdv.15608	https://pubmed.ncbi.nlm.nih.gov/31056788/
Wang D, Beck LA. Immunologic targets in atopic dermatitis and emerging therapies: An update. <i>Am J Clin Dermatol</i> . 2016;17(5):425-443. doi:10.1007/s40257-016-0205-5	https://pubmed.ncbi.nlm.nih.gov/27371134/
Zhou S, Qi F, Gong Y, Zhang J, Zhu B. Biological therapies for atopic dermatitis: A systematic review. <i>Dermatology</i> . 2021;237(4):542-552. doi:10.1159/000514535	https://pubmed.ncbi.nlm.nih.gov/33735876/

Atopic Dermatitis Associations and Foundations

Resource	Address
American Academy of Dermatology (AAD). Eczema Resource Center.	https://www.aad.org/public/diseases/eczema
American Academy of Pediatrics (AAP).	https://www.aap.org/en-us/Pages/Default.aspx
Asthma and Allergy Foundation of America (AAFA). Allergies. Atopic Eczema.	http://www.aafa.org/page/eczema.aspx
International Eczema Council (IEC).	https://www.eczemacouncil.org/
National Eczema Association.	https://nationaleczema.org/
National Eczema Society. Atopic Eczema.	http://www.eczema.org/atopic-eczema